Aptorum Group (Aptorum Group) Net Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Aptorum Group's Net Income for the six months ended in Dec. 2023 was $2.66 Mil. Aptorum Group's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Aptorum Group's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Aptorum Group's Net Margin % or its related term are showing as below:

APM' s Net Margin % Range Over the Past 10 Years
Min: -3872.58 Med: -1190.28 Max: 774.89
Current: -655.45

APM's Net Margin % is ranked worse than
68.09% of 1028 companies
in the Biotechnology industry
Industry Median: -154.79 vs APM: -655.45

Aptorum Group Net Margin % Historical Data

The historical data trend for Aptorum Group's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Net Margin % Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-3,492.90

774.89

-1,624.38

-756.17

-655.45

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %	Get a 7-Day Free Trial								-991.92	-357.69	-1,030.47	-1,273.09	-

Competitive Comparison of Aptorum Group's Net Margin %

For the Biotechnology subindustry, Aptorum Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptorum Group's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptorum Group's Net Margin % distribution charts can be found below:

* The bar in red indicates where Aptorum Group's Net Margin % falls into.

Aptorum Group Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Aptorum Group's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-2.825	/	0.431
	=	-655.45 %

Aptorum Group's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	2.662	/	0
	=	%

Aptorum Group (NAS:APM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Aptorum Group Net Margin % Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptorum Group (Aptorum Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.